Events Pharmacokinetics Small Molecule 
DrugBank
OCTOBER 17, 2024
Data Science in Lead Optimization and Drug Design Data science accelerates the lead optimization and drug design process, transforming how molecules are engineered for therapeutic applications. Furthermore, data-driven approaches can optimize clinical trial design, leading to smaller sample sizes and reduced overall costs.
Drug Target Review
SEPTEMBER 25, 2024
At TOLREMO, we have developed a proprietary modular phenotypic screening platform that leverages transcriptional reprogramming events associated with non-genetic resistance to deliver new chemical scaffolds and identify novel resistance regulators. Inhibiting KDM5A, a regulator of cell proliferation, poses another interesting approach.
The Pharma Data
NOVEMBER 17, 2020
The study demonstrated favorable proof-of-concept for LYT-100’s tolerability and pharmacokinetic (PK) profile, which will also enable twice-a-day (BID) dosing of LYT-100 in future studies. All adverse events (AEs) that were possibly or probably related to LYT-100 were mild and transient and there were no discontinuations. 1 Cottin, V.,
New Drug Approvals
SEPTEMBER 29, 2024
link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. All volunteers with AD had P. 2019 Jan;5(1):eaau3333.
LifeSciVC
APRIL 24, 2024
If adverse events are anticipated, it is important to understand gene dosage for such an effect (e.g., and whether a molecule’s pharmacology can help to mitigate safety risk. and whether a molecule’s pharmacology can help to mitigate safety risk. loss of function” (LoF) effect, but can also be quite nuanced (e.g.,
Drug Target Review
JUNE 12, 2023
The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.
The Pharma Data
JANUARY 17, 2021
18, 2021 /PRNewswire/ — Genkyotex SA , a subsidiary of Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX; NASDAQ – CALT), today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex’s lead asset. STOCKHOLM , Jan.
Expert insights. Personalized for you.
71 
Let's personalize your content